[1]郭 华a,齐宗利a,张海祥b,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17-20.[doi:10.3969/j.issn.1671-7414.2018.06.005]
　GUO Huaa,QI Zong-lia,ZHANG Hai-xiangb,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):17-20.[doi:10.3969/j.issn.1671-7414.2018.06.005]
点击复制

非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年06期
页码:
17-20
栏目:
论著
出版日期:
2018-12-24

文章信息/Info

Title:
Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer
文章编号:
1671-7414(2018)06-017-04
作者:
郭 华a; 齐宗利a; 张海祥b; 李真真a; 房国栋a; 李文生a
陕西省人民医院a.病理科; b.中心实验室,西安 710068
Author(s):
GUO Huaa; QI Zong-lia; ZHANG Hai-xiangb; LI Zhen-zhena; FANG Guo-donga; LI Wen-shenga
a. Department of Pathology; b.Central Laboratory,Shaanxi Provincial People's Hospital,Xi'an 710068,China
关键词:
非小细胞肺癌;  表皮生长因子受体;  间变性淋巴瘤激酶;  肉瘤致癌因子-受体酪氨酸激酶;  基因检测
分类号:
R734.2; R730.43
DOI:
10.3969/j.issn.1671-7414.2018.06.005
文献标志码:
A
摘要:
目的 探讨非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR),间变性淋巴瘤激酶(ALK)和肉瘤致癌因子-受体酪氨酸激酶(ROS1)三种基因突变联合检测的临床意义。方法 收集2017年1月～2018年7月患者NSCLC组织标本146例,采用过柱法提取DNA和RNA,突变检测采用RT-PCR法和扩增阻滞突变系统(ARMS)法。结果 EGFR/ALK/ROS1三联检的突变频率为41.8%(61/146),明显高于单基因检测突变率:EGFR(33.6%,49/146),ALK(6.8%,10/146)和ROS1(2.7%,4/146)。EGFR的不同突变类型的检出率如下:19Del 52.9%(27/51),L858R 41.2%(21/51),G719X,L861Q 5.9%(3/51); 其中还检出四例双突变标本:19Del+ L858R(1例),19Del+G719X,L861Q(1例),ALK+19Del(1例),ROS1+L858R(1例)。EGFR/ALK/ROS1阳性标本中女性(56.7%,30/53)明显高于男性(33.3%,31/93),两者比较差异有统计学意义(χ2=7.516,P=0.006),肺腺癌(47.9%,58/121)明显高于鳞癌(4.8%,1/21),差异具有统计学意义(χ2=13.733,P=0.000)。不同来源组织突变检出率为:手术切除肿瘤组织标本41.0%(32/78),细针穿刺活检及支气管镜刷检细胞学等标本43.4%(23/53),胸腔积液标本40.0%(6/15),三者比较差异无统计学意义(P>0.05)。结论 在NSCLC基因突变中:EGFR/ALK/ROS1三联检的突变频率明显高于EGFR,ALK和ROS1单基因检测。EGFR常见突变基因为19Ex Del和21Ex L858R。女性突变率明显高于男性。EGFR/ALK/ROS1的联合检测可一次获得更多基因突变信息,为靶向用药提供更多选择,尤其是对于临床稀有标本意义更大。
Abstract:
Objective To explore the clinical significanceof combined detection of three gene mutations in non-small cell lung cancer(NSCLC)patients:epidermal growth factor receptor(EGFR),mesenchymal lymphoma kinase(ALK)and sarcomao ncogene-receptor tyrosine kinase(ROS1).Methods From January 2017 to July 2018,146 patients with NSCLC tissue were collected in Shaanxi Province People's Hospital.DNA and RNA were extractedby centrifugal mini column methods.RT-PCR and amplification block mutation system(ARMS)method were employed in the mutation detection.ResultsThe gene mutation rate of EGFR/ALK/ROS1(41.8%,61/146)was significantly higher than that of EGFR(33.6%,49/146),ALK(6.8%,10/146)and ROS1(2.7%,4/146).The mutation rate of different mutation types of EGFR gene were asfollows:deletions at exon 19 was 52.9%(27/51),21Ex L858R was 41.2%(21/51),18Ex G719X,21Ex L861Q was 5.9%(3/51); Also co-mutation of 19 Del+ L858R(1sample),19Del+ G719X,L861Q(1 sample),ALK+19Del(1 sample),and ROS1+L858R(1 sample)in EGFR were detected.Among EGFR/ALK/ROS1 positive samples,women(56.7%,30/53)were higher than men(33.3%,31/93),the comparison was statistically significant(χ2=7.516,P=0.006),and lung adenocarcinoma(47.9%,58/121)was significantly higher than squamous cancer(4.8%,1/21), the comparison was statistically significant(χ2=13.733,P=0.000).The mutation detection rate of different source organizations were as follows:large tissue specimens(41.0%,32/78),fine needle biopsy and bronchoscopic brush cytology(43.4%,23/53),and pleural water specimens(40.0%,6/15).ConclusionIn the NSCLC gene mutation,the mutation frequency of EGFR/ALK/ROS1 was significantly higher than that of EGFR,ALK and ROS1 gene detection,and thecommon mutation genes of EGFR were 19Ex Del and 21Ex L858R.Female mutation ratewas significantly higher than male.The combined detection of EGFR/ALK/ROS1 canobtain more information of gene mutation at one time,providing more choices for targeted drugs,especially for rare clinical specimens.

参考文献/References:

[1] Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA-A Cancer Journal Clinicians,2015,65(2):87-108.
[2] 叶肖燕.非小细胞肺癌患者表皮生长因子受体基因突变特征及意义[J].中华实用诊断及治疗杂志,2016,30(1):49-51.
Ye XY.Characteristics and significance of epidermal growth factorreceptor gene mutation in non-small cell lung cancer[J].J Chin Practical Diagnosis and Therapy,2016,30(1):49-51.
[3] She J,Yang P,Hong QY,et al.Lung cancer in China challenges and interventions[J].Chest,2013,143(4):1117-1126.
[4] 赵建国,熊建萍.非小细胞肺癌驱动基因研究进展[J].中国肺癌杂志,2015,18(1):42-47.
Zhao JG,Xiong JP.Advances on driver oncogenes of non-small cell lung cancer[J].Chin J Lung Cancer,2015,18(1):42-47.
[5] 黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(5):16-18,23.
Lixie MD,Luo K,Wu SF,et al.Mutation analysis of EGFR,ALK and ROS1 in tumor tissues of patients with non-small cell lung cancer in south of China[J].J Mod Lab Med,2017,32(5):16-18,23.
[6] Yamamoto H,Toyooka S,Mitsudomi T.Impact of E-GFR mutation analysis innon-small cell lung cancer[J].Lung Cancer,2018,63(3):315-324.
[7] Shaw AT,Yeap BY,Solomon BJ,et al.Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK generearrangement:a retrospective analysis[J].Lancet Oncol,2011,12(11):1004-1012.
[8] Ou SH,Tan J,Yen Y,et al.ROS1 as a “druggable” receptor tyrosine kinase:lessons learned from inhibiting the ALK pathway[J].Expert Rev AnticancerTher,2012,12(4):447-456.
[9] Sholl L.Molecular diagnostics of lung cancer in the clinic[J].TranslLung Cancer Res,2017,6(5):560-569.
[10] Shao AT,Ou SH,Bang YJ,et al.Crizotinib in ROS1 rearranged non-small cell lung cancer[J].N Engl J Med,2014,371(21):1963-1971.
[11] 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家组.中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识(2016版)[J].中华病理学杂志,2016,45(4):217-220.
Expert Group for Detection of Epidermal Growth Fa-ctor Receptor Gene Mutation in Non-small Cell Lung Cancer Patients in China.Expert consensus on the detection of epidermal growth factor receptor gene mutation in non-small cell lung cancer patients in China(2016 edition)[J].Chin J Pathol,2016,45(4):217-220.
[12] Campbell JD,Alexandrov A,Kim J,et al.Distinct pa-tterns of somaticgenome alterations in lung adenocarcinomas and squamous cell carcinomas[J].Nat Genet,2016,48(6):607-616.
[13] Li SY,Choi YL,Gong ZL,et al.Comprehensive cha-racterization of oncogenic drivers in Asian lung adenocarcinoma[J].J Thorac Oncol,2016,11(12):2129-2140.
[14] 杨长绍,杨延龙,丁晓洁,等.非小细胞肺癌患者肿瘤组织多驱动基因联合检测及其临床意义[J]. 临床与实验病理学杂志,2017,33(11):1183-1187.
Yang CS,Yang YL,Ding XJ,et al.Driver gene mutations among non-small cell lung cancer tissues and its clinical significance[J].J Clin Exp Pathol,2017,33(11):1183-1187.
[15] Doss GP,Rajith B,Chakraborty C,et al.Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors[J].Sci Rep,2014,4:5868.
[16] Chiu CH,Yang CT,Shih JY,et al.Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations[J].J Thorac Oncol,2015,10(5):793-799.
[17] Barnet MB,O'Toole S,Horvath LG,et al.EGFR-Co-Mutated advanced NSCLC and response to EGFR tyrosine kinase inhibitors[J].J Thorac Oncol,2017,12(3):585-590.

相似文献/References:

[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
　ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
　XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
　WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR) Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(06):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3，CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
　YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3， CYFRA21-1，TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(06):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
　QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]李晓锋,刘 希,张冠军,等.ARMS法检测肺腺癌EGFR基因突变及临床意义[J].现代检验医学杂志,2018,33(02):42.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LI Xiao-feng,LIU XI,ZHANG Guan-jun,et al.Detection of EGFR Gene Mutation in Lung Adenocarcinoma by ARMS and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(06):42.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
　LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
　HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[9]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体（EGFR）基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
　JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor （EGFR）Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(06):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
[10]彭　琦a,程少鹏b,陈辅萍a.非小细胞肺癌组织中NSE 的基因表达及与患者临床特征的相关性研究[J].现代检验医学杂志,2020,35(03):36.[doi:10.3969/j.issn.1671-7414.2020.03.008]
　PENG Qia,CHENG Shao-pengb,CHEN Fu-pinga.Correlation between NSE Gene Expression and Serum NSE Level in Tumor Tissues and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2020,35(06):36.[doi:10.3969/j.issn.1671-7414.2020.03.008]
[11]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
　LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(06):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]

备注/Memo

备注/Memo:
基金项目:陕西省科技计划项目(2017SF-091); 陕西省卫生计生科研基金项目(2016D035)。
作者简介:郭 华(1977-),女,本科,主管检验师,从事分子病理学等研究,E-mail:guohua1123@163.com。
通讯作者:齐宗利(1967-),男,博士,研究员,从事病理学及肿瘤生物学研究,E-mail:qizongli@126.com
更新日期/Last Update: 2018-11-30